These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38734992)

  • 1. Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matching.
    Nakai Y; Tanaka N; Asakawa I; Ohnishi K; Miyake M; Yamaki K; Torimoto K; Fujimoto K
    Prostate; 2024 Sep; 84(12):1104-1111. PubMed ID: 38734992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life.
    Abdelhakiem MK; Keller A; Bajpai RR; Smith RP; Beriwal S; Benoit R
    Brachytherapy; 2023; 22(6):808-821. PubMed ID: 37648596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in patients who underwent robot-assisted radical prostatectomy compared with those who underwent low-dose-rate brachytherapy.
    Nakai Y; Tanaka N; Asakawa I; Hori S; Miyake M; Yamaki K; Anai S; Torimoto K; Inoue T; Hasegawa M; Fujimoto K
    Prostate; 2023 May; 83(7):701-712. PubMed ID: 36879383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.
    Tsubokura T; Yamazaki H; Masui K; Sasaki N; Shimizu D; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Nishikawa T; Okabe H
    Sci Rep; 2018 Jul; 8(1):10538. PubMed ID: 30002393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
    Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
    Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer.
    Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Hori S; Morizawa Y; Tatsumi Y; Hasegawa M; Fujii T; Fujimoto K
    J Radiat Res; 2019 Mar; 60(2):270-280. PubMed ID: 30576565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy.
    Crook J; Moideen N; Arbour G; Castro F; Araujo C; Batchelar D; Halperin R; Hilts M; Kim D; Petrik D; Rose J; Cheng JC; Bachand F
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):59-68. PubMed ID: 38493901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer.
    Ong WL; Evans M; Papa N; Williams S; Millar J
    J Med Imaging Radiat Oncol; 2023 Oct; 67(7):789-795. PubMed ID: 37828817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
    Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K
    BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
    Patel AK; Houser C; Benoit R; Smith RP; Beriwal S
    Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
    Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
    Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
    Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
    Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison.
    Ogita M; Yamashita H; Nozawa Y; Ozaki S; Sawayanagi S; Ohta T; Nakagawa K
    Radiat Oncol; 2021 Jun; 16(1):107. PubMed ID: 34118956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial.
    Hamstra DA; Mariados N; Sylvester J; Shah D; Gross E; Hudes R; Beyer D; Kurtzman S; Bogart J; Hsi RA; Kos M; Ellis R; Logsdon M; Zimberg S; Forsythe K; Zhang H; Soffen E; Francke P; Mantz C; Rossi P; DeWeese T; Daignault-Newton S; Fischer-Valuck BW; Chundury A; Gay HA; Bosch W; Michalski J
    Pract Radiat Oncol; 2018; 8(1):e7-e15. PubMed ID: 28951089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.
    Mahal BA; Ziehr DR; Hyatt AS; Neubauer-Sugar EH; O'Farrell DA; O'Leary MP; Steele GS; Niedermayr TR; Beard CJ; Martin NE; Orio PF; D'Amico AV; Devlin PM; Nguyen PL
    Brachytherapy; 2014; 13(5):442-9. PubMed ID: 24880584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
    BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.